MIRA INFORM REPORT

 

 

Report Date :

05.12.2013

 

IDENTIFICATION DETAILS

 

Name :

UNICHEM LABORATORIES LIMITED

 

 

Registered Office :

Unichem Bhavan, Prabhat Estate, Off S. V. Road, Jogeshwari (West), Mumbai – 400102, Maharashtra

 

 

Country :

India

 

 

Financials (as on) :

31.03.2013

 

 

Date of Incorporation :

22.08.1962

 

 

Com. Reg. No.:

11-012451

 

 

Capital Investment / Paid-up Capital :

Rs. 180.913 Millions

 

 

CIN No.:

[Company Identification No.]

L99999MH1962PLC012451

 

 

TAN No.:

[Tax Deduction & Collection Account No.]

PNEU05493F

 

 

PAN No.:

[Permanent Account No.]

AAACU0551B

 

 

Legal Form :

A Public Limited Liability Company. The Company’s Shares are Listed on the Stock Exchanges.

 

 

Line of Business :

Manufacturer of Active Pharmaceutical Ingredients (APIs).

 

 

No. of Employees :

4592 (Approximately)

 

 

RATING & COMMENTS

 

MIRA’s Rating :

A (64)

 

RATING

STATUS

PROPOSED CREDIT LINE

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

Fairly Large

 

Maximum Credit Limit :

USD 32500000

 

 

Status :

Good

 

 

Payment Behaviour :

Regular

 

 

Litigation :

Exist

 

 

Comments :

Subject is a well-esatablished company having good track record.

 

The financial position of the company appears to be good. Fundamental are strong and healthy.

 

Trade relations are are reported to be fair. Business is active. Payments are reported to be regular and as per commitment.

 

The company can be considered for business dealing at usual trade terms and conditions.

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March 31st, 2013

 

Country Name

Previous Rating

(31.12.2012)

Current Rating

(31.03.2013)

India

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

INDIAN ECONOMIC OVERVIEW

 

The current downturn provides an opportunity to push ahead with reforms to accelerate growth, says the latest India Development Update report released by the World Bank. The report says that the adverse effects of rupee depreciation are likely to be offset by the gains in the exports performance due to improved external competitiveness. Since May this year, the local currency has depreciated substantially and fell to a record level of Rs 68.85 to a dollar on August, 28.

 

A stagflation like situation appears to have arisen as inflation jumped to an eight month high of 6.46 % for the month of September. It is up from 6.10 % in August. Growth continues to be muted with factory output plunging to 0.6  % in August. Onion prices have risen nearly 300 % from last September. Vegetables cost nearly 90 % more than they did last year. Wake up to the economic contribution of slum dwellers. They contribute more than 7.5 % to the country’s gross domestic product, according to a recent study conducted in 50 top cities.

 

136000 estimated number of jobs created during the second quarter of the current financial year. 50000 estimated number of additional jobs in the field of corporate social responsibility in the coming years.

 

The International Finance Corporation expects to come out with its rupee linked bonds issue before the end of 2013 as a part of its plan to raise $ 1 billion. The Apple iPhone 5c (Rs 41900 for 16 GB variant) and 5s (Rs 53500 for 16GB variant) has been launched in India from 1st November.

 

The Land Acquisition Act to provide just and fair compensation to farmers will come into force from January 1 next year, said Rural Development Minister Jairam Ramesh. The Act replaces a 119 year old registration. The Securities and Exchange Board of India has approved the trading of currency futures on the Bombay Stock Exchange. The exchange plans to launch the currency futures platform with advanced trading technology by the end of November.

 

 

EXTERNAL AGENCY RATING

 

Rating Agency Name

ICRA

Rating

Short term debt: A1+

Rating Explanation

Very strong degree of safety and lowest credit risk.

Date

October, 2012

 

 

RBI DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available RBI Defaulters’ list.

 

 

EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of 31-03-2012.

 

 

INFORMATION DECLINED

 

MANAGEMENT NON-COOPERATIVE (Tel. No.: 91-22-66888333)

 

 

LOCATIONS

 

Registered / Corporate Office :

Unichem Bhavan, Prabhat Estate, Off S. V. Road, Jogeshwari (West), Mumbai – 400102, Maharashtra, India

Tel. No.:

91-22-26780643 / 66888333 / 26785616

Fax No.:

91-22-26784391/ 26794089 / 26788665

E-Mail :

info@unichem.com

info@unichemindia.com

shares@unichemlabs.com

Website :

www.unichemindia.com

www.unichemlabs.com

 

 

Head Office :

Mahalaxmi Chambers, 2nd Floor, 22 Bhulabhai Desai Road, Mumbai – 400026, Maharashtra, India

 

 

Factory 1:

Plot No. 17 and 18, Pilerne Industrial Estate, Pilerne Bardez, Goa – 403515, India

Tel. No.:

91-832-2407202/ 6

 

 

Factory 2

Bhatauli Kalan District, Solan, Baddi – 173 205, Himachal Pradesh, India

Tel. No.:

91-1795-246701/ 6

 

 

Factory 3 :

C-31-32, Industrial Area, Meerut Road, Ghaziabad – 173205, Uttar Pradesh, India

Tel. No.:

91-120-2750039/ 46

 

 

Factory 4:

99, MIDC Area, Roha, District Raigad – 402116, Maharashtra, India

Tel. No.:

91-2194-263561/263549

 

 

Factory 5 :

Pithampur, Plot No 197, Sector – I, Pithampur –454775, Madhya Pradesh, India

Tel. No.:

91-729-2503127/ 2500941

 

 

Factory 6:

NH – 31A, Bagheykhola, Majithar, Rangpo, East Sikkim – 737138, India

 

 

Factory 7:

Plot Nos. 11, 12 & 13 Pharma Zone, Phase II, Sector 3, Pithampur, District Dhar-454775, Madhya Pradesh, India

 

 

Representative Offices 1:

St. Bolshaya Yakimanka Hno 31/18, Moscow, Russia

Tel. No.:

+ 7 095 2302380

Fax No.:

+ 7 095 2387934

E-Mail :

unichemindia@mail.ru

 

 

Representative Offices 2:

2/1, Kruglouniversityskya, Office # 3 Ukraine, Kiev - 012024

Tel. No.:

+ 380 44 235 24 05 / 4280160

 

 

DIRECTORS

 

As on 31.03.2013

 

Name :

Dr. Prakash A. Mody

Designation :

Chairman and Managing Director

 

 

Name :

Mr. Prafull Anubhai

Designation :

Independent Director

 

 

Name :

Mr. Ramdas Gandhi

Designation :

Independent Director

 

 

Name :

Mr. Nasser Munjee

Designation :

Independent Director

 

 

Name :

Mr. Prafull D. Sheth

Designation :

Independent Director

 

 

Name :

Mr. Anand Mahajan

Designation :

Independent Director

 

 

KEY EXECUTIVES

 

Audit Committee :

·         Mr. Prafull Anubhai - Chairman

·         Mr. Ramdas Gandhi

·         Mr. Nasser Munjee

 

 

Shareholders’ Grievance Committee:

·         Mr. Ramdas Gandhi - Chairman

Dr. Prakash A. Mod

 

 

Compensation Committee :

·         Mr. Prafull D. Sheth - Chairman

·         Mr. Prafull Anubhai

·         Mr. Ramdas Gandhi

 

 

Name :

Mr. K. Subharaman

Designation :

Company Secretary and Compliance Officer

 

 

MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN

 

As on 30.09.2013

 

Names of Shareholders

No. of Shares

Percentage of Holding

(A) Shareholding of Promoter and Promoter Group

 

 

http://www.bseindia.com/include/images/clear.gif(1) Indian

 

 

http://www.bseindia.com/include/images/clear.gifIndividuals / Hindu Undivided Family

45378350

50.09

http://www.bseindia.com/include/images/clear.gifAny Others (Specify)

132200

0.15

http://www.bseindia.com/include/images/clear.gifTrusts

132200

0.15

http://www.bseindia.com/include/images/clear.gifSub Total

45510550

50.24

http://www.bseindia.com/include/images/clear.gif(2) Foreign

 

 

Total shareholding of Promoter and Promoter Group (A)

45510550

50.24

(B) Public Shareholding

 

 

http://www.bseindia.com/include/images/clear.gif(1) Institutions

 

 

http://www.bseindia.com/include/images/clear.gifMutual Funds / UTI

6564366

7.25

http://www.bseindia.com/include/images/clear.gifFinancial Institutions / Banks

182010

0.20

http://www.bseindia.com/include/images/clear.gifInsurance Companies

3013679

3.33

http://www.bseindia.com/include/images/clear.gifForeign Institutional Investors

3344145

3.69

http://www.bseindia.com/include/images/clear.gifAny Others (Specify)

500

0.00

http://www.bseindia.com/include/images/clear.gifForeign Financial Institutions / Banks

500

0.00

http://www.bseindia.com/include/images/clear.gifSub Total

13104700

14.47

http://www.bseindia.com/include/images/clear.gif(2) Non-Institutions

 

 

http://www.bseindia.com/include/images/clear.gifBodies Corporate

8617182

9.51

http://www.bseindia.com/include/images/clear.gifIndividuals

 

 

http://www.bseindia.com/include/images/clear.gifIndividual shareholders holding nominal share capital up to Rs. 0.100 Million

17934860

19.80

http://www.bseindia.com/include/images/clear.gifIndividual shareholders holding nominal share capital in excess of Rs. 0.100 Million

2652166

2.93

http://www.bseindia.com/include/images/clear.gifAny Others (Specify)

2767143

3.05

http://www.bseindia.com/include/images/clear.gifTrusts

964870

1.07

http://www.bseindia.com/include/images/clear.gifDirectors & their Relatives & Friends

134855

0.15

http://www.bseindia.com/include/images/clear.gifNon Resident Indians

723880

0.80

http://www.bseindia.com/include/images/clear.gifClearing Members

52315

0.06

http://www.bseindia.com/include/images/clear.gifHindu Undivided Families

866223

0.96

http://www.bseindia.com/include/images/clear.gifForeign Corporate Bodies

16250

0.02

http://www.bseindia.com/include/images/clear.gifForeign Nationals

8750

0.01

http://www.bseindia.com/include/images/clear.gifSub Total

31971351

35.29

Total Public shareholding (B)

45076051

49.76

Total (A)+(B)

90586601

100.00

(C) Shares held by Custodians and against which Depository Receipts have been issued

 

 

http://www.bseindia.com/include/images/clear.gif(1) Promoter and Promoter Group

0

0.00

http://www.bseindia.com/include/images/clear.gif(2) Public

0

0.00

http://www.bseindia.com/include/images/clear.gifSub Total

0

0.00

Total (A)+(B)+(C)

90586601

100.00

 

 

 

BUSINESS DETAILS

 

Line of Business :

Manufacturer of Active Pharmaceutical Ingredients (APIs).

 

 

Products :

Item Code No. (ITC Code)

Product Description

300410.06

 

Ampicillin and Cloxacillin in Capsules, Injections, etc.

300420.07

Rifampicin Formulations

293329.02

Metronidazole, Metronidazole Benzoate and other Salts

300490.05

Losartan Potassium in Tablets

300490.13

Alprazolam in Tablets

 

 

Brand Name:

·         LOSAR

AMPOXIN

UNIENZYME

TELSAR

TRIKA

 

 

GENERAL INFORMATION

 

No. of Employees :

4592 (Approximately)

 

 

Bankers :

·         Bank of India

The Sakura Bank Limited

Bank of Baroda

 

 

Facilities :

SECURED LOANS

31.03.2013

(Rs. in Millions)

31.03.2012

(Rs. in Millions)

SHORT TERM BORROWINGS

 

 

Cash Credit from Banks

57.205

94.914

Total

57.205

94.914

 

Banking Relations :

--

 

 

Auditors :

 

Name :

B D Jokhakar and Company

Chartered Accountant

Address :

8 Ambalal Doshi Marg, Fort, Mumbai – 400001, Maharashtra, India

 

 

Subsidiaries :

·         Niche Generics Limited

Unichem SA Pty Ltd.

Unichem Farmaceutica Do

Brasil Ltda

Unichem Pharmaceuticals

(USA) Inc

Unichem Laboratories Limited (Incorporated in Ireland)

 

 

Enterprises under significant influence of key management personnel:

·         Chevy Capital Services Private Limited*

PM Capital Services Private Limited *

AVM Capital Services Private Limited *

Pranit Trading Private Limited *

Viramrut Trading Private Limited *

Uni Distributors Private Limited

 

* Scheme of amalgamation becoming effective from 01.04.2011 (appointed date) consequent upon sanction from Hon'ble High court of Mumbai, shares in the name of said companies were cancelled and new shares were issued to the

shareholders of respective companies. However considering the fact that Dividend was paid before effective date, the transactions are reflected hereunder in spite of cancellation of the shares w.e.f. 01.04.2011.

 

 

CAPITAL STRUCTURE

 

As on 19.07.2013

 

Authorised Capital : Rs. 500.000 Millions

 

Issued, Subscribed & Paid-up Capital : Rs. 181.194 Millions

 

 

As on 31.03.2013

 

Authorised Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

175,000,000

Equity Shares

Rs.2/- each

Rs.350.000 Millions

50,000,000

Unclassified Shares

Rs.2/- each

Rs.100.000 Millions

5,000,000

Preference Shares

Rs.10/- each

Rs. 50.000 Millions

 

 

 

 

 

Total

 

Rs. 500.000 Millions

 

Issued, Subscribed & Paid-up Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

90,321,502

Equity Shares

Rs.2/- each

Rs.180.643 Millions

 

 

 

 

 

Note:

 

Particulars

31.03.2013

Reconciliation of Number of Shares (Equity)

Number of shares

Rs. in millions

Number of Shares outstanding as at the beginning of the year*

90,321,501

180.643

Add: Number of Shares allotted under ESOP during the year

134,937

0.270

Number of Shares outstanding as at the end of the year*

90,456,438

180.913

 

* Excluding effect of amalgamation

 

Rights, preferences and restrictions attached to Equity Shares.

 

The company has one class of equity shares having a par value of Rs. 2/- per share. Each shareholder is eligible for one vote per share held. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting, except in case of interim dividend. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the Company after distribution of all preferential amounts, in proportion to their shareholding.

 

Shareholders holding more than 5 per cent of total Equity Shares of company

 

Name of the Shareholders

31.03.2013

Number of shares

Rs. in millions

 

 

 

Dr. Prakash Amrut Mody**

39,845,639

44.05

 

 

 

 

As per the of the Company, including its register of shareholders / members and other declarations received from shareholders regarding beneficial interest , the above shareholding represents both legal and beneficial ownership of shares.

 

** Scheme of amalgamation becoming effective from 01.04.2011 (appointed date) consequent upon sanction from Hon'ble High court of Mumbai , new shares were issued to the shareholders of respective companies the effect of which was not included in shareholding as of 31st March , 2012

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FINANCIAL DATA

[all figures are in Rupees Millions]

 

ABRIDGED BALANCE SHEET

 

SOURCES OF FUNDS

 

31.03.2013

31.03.2012

31.03.2011

I.        EQUITY AND LIABILITIES

 

 

 

(1)Shareholders' Funds

 

 

 

(a) Share Capital

180.913

180.643

180.479

(b) Reserves & Surplus

7948.615

7119.527

6599.760

(c) Money received against share warrants

0.000

0.000

0.000

 

 

 

 

(2) Share Application money pending allotment

0.000

0.345

0.000

Total Shareholders’ Funds (1) + (2)

8129.528

7300.515

6780.239

 

 

 

 

(3) Non-Current Liabilities

 

 

 

(a) long-term borrowings

0.000

0.000

227.156

(b) Deferred tax liabilities (Net)

389.743

384.743

378.143

(c) Other long term liabilities

252.576

234.882

0.000

(d) long-term provisions

91.868

102.392

79.020

Total Non-current Liabilities (3)

734.187

722.017

684.319

 

 

 

 

(4) Current Liabilities

 

 

 

(a) Short term borrowings

57.205

248.729

84.727

(b) Trade payables

1590.860

1367.850

1069.163

(c) Other current liabilities

298.668

292.296

226.888

(d) Short-term provisions

516.696

333.000

311.256

Total Current Liabilities (4)

2463.429

2241.875

1692.034

 

 

 

 

TOTAL

11327.144

10264.407

9156.592

 

 

 

 

II.      ASSETS

 

 

 

(1) Non-current assets

 

 

 

(a) Fixed Assets

 

 

 

(i) Tangible assets

4147.030

3708.096

3556.443

(ii) Intangible Assets

115.148

144.014

0.000

(iii) Capital work-in-progress

1292.905

1113.424

628.716

(iv) Intangible assets under development

0.000

0.000

0.000

(b) Non-current Investments

1072.030

916.193

788.547

(c) Deferred tax assets (net)

0.000

0.000

0.000

(d)  Long-term Loan and Advances

83.781

260.225

162.914

(e) Other Non-current assets

0.000

0.000

0.000

Total Non-Current Assets

6710.894

6141.952

5136.620

 

 

 

 

(2) Current assets

 

 

 

(a) Current investments

330.604

145.000

212.888

(b) Inventories

1316.339

1411.311

1354.183

(c) Trade receivables

2122.764

1848.247

1839.423

(d) Cash and cash equivalents

166.600

138.612

104.412

(e) Short-term loans and advances

639.142

534.990

479.118

(f) Other current assets

40.801

44.295

29.948

Total Current Assets

4616.250

4122.455

4019.972

 

 

 

 

TOTAL

11327.144

10264.407

9156.592

 

 

PROFIT & LOSS ACCOUNT

 

 

PARTICULARS

31.03.2013

 

31.03.2012

31.03.2011

 

SALES

 

 

 

 

 

Income

10052.169

8031.873

7647.374

 

 

Other Income

140.670

93.947

79.622

 

 

TOTAL                                     (A)

10192.839

8125.820

7726.996

 

 

 

 

 

Less

EXPENSES

 

 

 

 

 

Cost of materials consumed

2612.792

1942.855

1773.866

 

 

Purchase of Stock -in-Trade

1078.443

1029.078

1016.127

 

 

Employee benefits expenses

1280.150

1048.840

930.663

 

 

Other expenses

2762.206

2377.682

2168.426

 

 

Research & Development Expenses

361.073

379.402

366.832

 

 

Changes in inventories of Finished goods, Work-in-progress and Stock -in-Trade

100.731

(20.258)

(222.376)

 

 

TOTAL                                     (B)

8195.395

6757.599

6033.538

 

 

 

 

 

Less

PROFIT BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (A-B)      (C)

1997.444

1368.221

1693.458

 

 

 

 

 

Less

FINANCIAL EXPENSES                         (D)

24.816

32.985

19.482

 

 

 

 

 

 

PROFIT BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D)                                       (E)

1972.628

1335.236

1673.976

 

 

 

 

 

Less/ Add

DEPRECIATION/ AMORTISATION                     (F)

348.165

282.881

272.177

 

 

 

 

 

 

PROFIT BEFORE TAX (E-F)                               (G)

1624.463

1052.355

1401.799

 

 

 

 

 

Less

TAX                                                                  (H)

328.503

227.722

316.821

 

 

 

 

 

 

PROFIT AFTER TAX (G-H)                                (I)

1295.960

824.633

1084.978

 

 

 

 

 

Add

Addition on Amalgamation

0.000

0.162

0.000

 

 

 

 

 

Add

PREVIOUS YEARS’ BALANCE BROUGHT FORWARD

4783.652

4424.220

3909.169

 

 

 

 

 

Less

APPROPRIATIONS

 

 

 

 

 

Proposed Dividend

407.116

271.344

252.671

 

 

Interim Dividend

0.000

0.000

108.283

 

 

Tax on Proposed Dividend

69.189

44.019

40.989

 

 

Tax on Interim Dividend

0.000

0.000

17.984

 

 

Transfer to General Reserve

150.000

150.000

150.000

 

BALANCE CARRIED TO THE B/S

5453.307

4783.652

4424.220

 

 

 

 

 

 

EARNINGS IN FOREIGN CURRENCY

 

 

 

 

 

Export Goods calculated on FOB Basis

3215.711

2236.201

1458.551

 

 

Insurance, Freight and other charges recovered

135.125

93.123

46.060

 

TOTAL EARNINGS

3350.836

2329.324

1504.611

 

 

 

 

 

 

IMPORTS

 

 

 

 

 

Raw Materials

387.807

355.575

310.674

 

 

Packing Materials

23.239

31.891

14.541

 

 

Stores & Spares

2.199

1.176

6.129

 

 

Capital Goods

83.163

262.336

192.768

 

TOTAL IMPORTS

496.408

650.978

524.112

 

 

 

 

 

 

Earnings Per Share (Rs.)

 

 

 

 

Basic

14.33

9.13

12.03

 

Diluted

14.29

9.09

11.95

 

 

QUARTERLY RESULTS

 

PARTICULARS

 

 

30.06.2013

30.09.2013

Type

 

1st Quarter

2nd Quarter

Net Sales

 

2655.800

2695.700

Total Expenditure

 

2147.200

2193.600

PBIDT (Excl OI)

 

508.600

502.100

Other Income

 

76.100

77.000

Operating Profit

 

584.700

579.200

Interest

 

6.200

6.500

Exceptional Items

 

0.000

0.000

PBDT

 

578.500

572.700

Depreciation

 

106.800

109.800

Profit Before Tax

 

471.700

462.900

Tax

 

110.700

100.800

Provisions and contingencies

 

0.000

0.000

Profit After Tax

 

361.000

362.100

Extraordinary Items

 

0.000

0.000

Prior Period Expenses

 

0.000

0.000

Other Adjustments

 

0.000

0.000

Net Profit

 

361.000

362.100

 

 

KEY RATIOS

 

PARTICULARS

 

 

31.03.2013

 

31.03.2012

31.03.2011

PAT / Total Income

(%)

12.71

10.15

14.04

 

 

 

 

 

Net Profit Margin

(PBT/Sales)

(%)

16.16

13.10

18.33

 

 

 

 

 

Return on Total Assets

(PBT/Total Assets}

(%)

18.13

 

12.78

18.11

 

 

 

 

 

Return on Investment (ROI)

(PBT/Networth)

 

0.20

0.14

0.21

 

 

 

 

 

Debt Equity Ratio

(Total Debt/Networth)

 

0.01

0.03

0.05

 

 

 

 

 

Current Ratio

(Current Asset/Current Liability)

 

1.87

1.84

2.38

 

 

LOCAL AGENCY FURTHER INFORMATION

 

Sr. No.

Check List by Info Agents

Available in Report (Yes / No)

1]

Year of Establishment

Yes

2]

Locality of the firm

Yes

3]

Constitutions of the firm

Yes

4]

Premises details

No

5]

Type of Business

Yes

6]

Line of Business

Yes

7]

Promoter's background

Yes

8]

No. of employees

Yes

9]

Name of person contacted

No

10]

Designation of contact person

No

11]

Turnover of firm for last three years

Yes

12]

Profitability for last three years

Yes

13]

Reasons for variation <> 20%

-----

14]

Estimation for coming financial year

No

15]

Capital in the business

Yes

16]

Details of sister concerns

Yes

17]

Major suppliers

No

18]

Major customers

No

19]

Payments terms

No

20]

Export / Import details (if applicable)

No

21]

Market information

-----

22]

Litigations that the firm / promoter involved in

Yes

23]

Banking Details

Yes

24]

Banking facility details

Yes

25]

Conduct of the banking account

-----

26]

Buyer visit details

-----

27]

Financials, if provided

Yes

28]

Incorporation details, if applicable

Yes

29]

Last accounts filed at ROC

Yes

30]

Major Shareholders, if available

Yes

31]

Date of Birth of Proprietor/Partner/Director, if available

No

32]

PAN of Proprietor/Partner/Director, if available

No

33]

Voter ID No of Proprietor/Partner/Director, if available

No

34]

External Agency Rating, if available

Yes

 

UNSECURED LOANS

 

PARTICULAR

31.03.2013

(Rs. in Millions)

31.03.2012

(Rs. in Millions)

SHORT TERM BORROWINGS

 

 

Working capital loans in Foreign Currency from Banks

0.000

153.815

Total

0.000

153.815

 

CASE DETAILS

 

Lodging No.:-

CHSL/88/2008

Filing Date:-

18/01/2008

Reg. No.:-

CHS/88/2008

Reg. Date:-

18/01/2001

 

Lodging No.:-

ITXAL/2126/2006

 

Petitioner:-

The commissioner of Income Tax – 5,

Respondent:-

M/S Unichem Laboratories Limited

Petn.Adv.:-

R. Asokan (0)

 

 

District:-

Bombay

 

 

 

Bench:-

DIVISION

 

 

Status:-

Pre-Admission

Category:

NOTICE OF MOTION (APPEAL)

 

SCHEME OF AMALGAMATION

 

The Hon’ble High Court of Mumbai, on July 12, 2012 sanctioned the scheme of amalgamation under Section 391 to394 of the Companies Act,1956 of five Investment Companies (the primary assets of which comprise of equity shares in the Company) namely AVM Capital Services Private Limited (ACSPL), Chevy Capital Services Private Limited (CCSPL) , PM Capital Services Private Limited (PCSPL), Pranit Trading Private Limited (PTPL), Viramrut Trading Private Limited (VTPL), (collectively herein after referred to as ‘Transferor Companies’) with the Company. The Scheme was earlier approved by the shareholders in the court–convened meeting held on November 3, 2011. The Company filed the Court Order with the Registrar of Companies on 6th August, 2012 to make the scheme effective in terms of said order dated 12th July 2012. ULL has given effect for the said Scheme in its books of accounts with effect from the appointed date i.e. 1st April 2011. In accordance with the Scheme, the Company has accounted for the Amalgamation based on the “Pooling of Interest” method as under:

 

(i) all assets and liabilities appearing in the books of accounts of Transferor Companies have been transferred  to & vested in and have been recorded by the Company at their respective book values

 

 

(ii) the investments in equity share capital of the Company as it appeared in the books of account of the Transferor Companies is cancelled

 

(iii) the excess of net assets value of the Transferor Companies as reduced by the face value of shares issued by

the Company, adjusted for cancellation of equity share capital as mentioned above and net of all expenses in relation to the Scheme, amounting to Rs. 0.162 Millions has been credited to Surplus in the Profit and Loss Account

 

(iv) all inter-company transactions have been eliminated on incorporation of the accounts of Transferor Companies in the books of Company

 

(v) in consideration of the above, the Company issued and allotted equity shares, credited as fully paid up, to the extent indicated below, to all the members of the Transferor Companies in the following proportion:

 

(a) 46,72,552 fully paid up equity shares of Rs. 2 each of the Company for every 1,000 paid up equity shares of Rs. 100 each held in ACSPL

(b) 78,43,811 fully paid up equity shares of Rs. 2 each of the Company for every 1,000 paid up equity shares of Rs. 100 each held in CCSPL

(c) 46,70,186 fully paid up equity shares of Rs. 2 each of the Company for every 1,000 paid up equity shares of Rs. 100 each held in PCSPL

(d) 1,09,36,087 fully paid up equity shares of Rs. 2 each of the Company for every 1,000 paid up equity shares of Rs. 100 each held in PTPL

(e) 17,13,547 fully paid up equity shares of Rs. 2 each of the Company for every 1,000 paid up equity shares of Rs. 100 each held in VTPL

 

Accordingly, 2,82,93,991 fully paid up equity shares of Rs. 2 each of the Company were issued to the shareholders of the Transferor Companies, which is equivalent to the shares cancelled, vide (ii) above; these shares, aggregating to Rs. 56.588 Millions, pending allotment were shown as “Share Capital pending allotment” under Share Capital, thus resulting in no change in the total issued and paid up Share Capital of the Company. The new equity shares issued as above rank pari-passu with the existing equity shares of the Company. As per the scheme of amalgamation, the said shares were issued and allotted to the shareholders of the transferor companies as per register of members of the transferor companies as on the effective date i.e. 6th August, 2012.

 

 

REVIEW OF OPERATIONS

 

During the year, Sales/Income from operations (Net) increased to Rs. 10052.169 Millions in 2012-13 from Rs. 8031.873 Millions in 2011-12, registering a growth of 25.15%. Consolidated Sales/Income from operations (Net) stood at Rs. 10808.028 Millions as compared to Rs. 8754.630 Millions registering an increase of 23.45%. Appropriations The Company has transferred Rs. 150.000 Millions to the General Reserve during the year. An amount of Rs. 5453.307 Millions is proposed to be carried forward from the Profit and Loss Account.

 

 

REVIEW OF SUBSIDIARIES

 

NICHE GENERICS LIMITED

 

Niche Generics Limited is a wholly-owned subsidiary of the Company. It is engaged in manufacturing formulations and dossier filing in European markets. It recorded sales of GBP 107.68 Lacs for the year ended March 31, 2013 as compared to GBP 103.20 Lacs for the previous year ended March 31, 2012. The profit for the year ended March 31, 2013 stood at GBP 0.99 Lacs compared to the loss of GBP 1.90 lacs for the year ended March 31, 2012.

 

 

UNICHEM PHARMACEUTICALS (USA) INC.

 

Unichem Pharmaceuticals (USA) Inc., a wholly-owned subsidiary of the Company in USA, has been set up for business development, filing of ANDA's and exploring the opportunities for marketing alliances in North American markets. The subsidiary recorded sales of USD 82.48 Lacs for the year ended March 31, 2013 as compared to USD 52.13 Lacs for the previous year ended March 31, 2012 and incurred loss of USD 6.23 Lacs for the same period compared to the loss of USD 7.48 lacs for the year ended March 31, 2012.

 

Unichem Farmaceutica Do Brasil Ltda Unichem Farmaceutica Do Brasil Ltda., is a wholly- owned subsidiary of the Company in Brazil. This subsidiary has been set-up to own product registrations, launch generic and branded generics products in the Brazilian market. The subsidiary plans to have marketing alliances for promoting, warehousing and distribution. The entity suffered a loss of Brazilian Reals 29.61 Lacs in the current year as against Brazilian Reals 24.80 lacs during the previous year.

 

 

UNICHEM SA (PROPRIETARY) LIMITED

 

Unichem SA (Proprietary) Limited is a wholly-owned subsidiary of the Company in South Africa. This subsidiary has been set-up for business development and to own product registrations. The subsidiary has suffered a marginal loss of SA Rand 72 in the current year as compared to loss of SA Rand 6,113 for the previous year ended March 31, 2012.

 

 

UNICHEM LABORATORIES LIMITED IRELAND

 

Unichem Laboratories Ltd, Ireland is a wholly-owned subsidiary of the Company in Ireland. This subsidiary was incorporated last year for business development and to own product registrations. The subsidiary during the current year has suffered a loss of Euro 2.95 lacs as compared to loss of Euro 0.09 lacs for the previous year ended March 31, 2012

 

 

CONTINGENT LIABILITIES:

 

Particulars

31.03.2013

(Rs. in Millions)

31.03.2012

(Rs. in Millions)

(i) Claims not acknowledged as debts*.

179.099

141.600

(ii) In respect of the Guarantees given to Bank on behalf of :

 

 

- Subsidiaries

210.210

239.715

(iii) Other money for which the company is Contingently liable

49.591

51.893

TOTAL

438.900

433.208

 

* includes Rs. 9.644 Millions (Previous Year Rs. 8.820 Millions) paid under protest/deposit pending adjudication under Income tax Act,1961 and Central Excise Act 1944.

 

 

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2013

(Rs. In Millions)

 

Particulars

Quarter Ended

 

Three months

 ended

30.09.2013

Three months

 ended

30.06.2013

Half year

ended

30.09.2013

 

(Unaudited)

(Unaudited)

(Unaudited)

1

a. Net Sales/Income from operations (Net of excise duty)

2661.875

2622.046

5283.921

 

b. Other Operating Income

33.837

33.742

67.579

 

Total Income from Operations (Net)

 

 

 

2

EXPENSES

 

 

 

 

a. Cost of Materials Consumed

666.156

655.238

1321.394

 

b. Purchase of Stock-in-Trade

332.103

351.027

683.130

 

c. Changes in inventories of finished goods, work-in-progress and stock-in-trade

(56.227)

(46.712)

(102.939)

 

d. Employee Benefits Expenses

414.491

413.181

827.672

 

e. Depreciation and amortisation Expense

109.797

106.818

216.615

 

f. Other Expenses

837.073

774.481

1611.554

 

Total Expenses

2303.393

2254.033

4557.426

3

Profit  from  Operations   before  Other Income,  Finance Costs & Exceptional Items (1-2)

392.319

401.755

794.074

4

Other Income

77.042

76.099

153.141

5

Profit/ (Loss) Before Finance Costs & Exceptional Items   (3+4)

469.361

477.854

947.215

6

Finance Costs

6.488

6.167

12.655

7

Profit/ (Loss)  after Finance Cost but before exceptional items (5-6)

462.873

471.687

934.560

8

Exceptional Items

--

--

--

9

Profit/ (Loss) ordinary activities before Tax (7-8)

462.873

471.687

934.560

10

Tax Expenses (Including Deferred tax)

100.800

110.700

211.500

11

11 Net profit from ordinary activities after tax ( 9 -10 )

362.073

360.987

723.060

12

Prior period Expenses / (Income)

--

--

--

13

Excess / (Short) provision for taxation pertaining to earlier years.

--

--

--

14

Net profit from ordinary activities after tax and prior period items ( 11-12-13)

362.073

360.987

723.060

15

Extraordinary items (net of tax expense)

--

--

--

16

Net profit for the period (14-15)

362.073

360.987

723.060

17

Paid up Equity Share Capital (Face Value Rs. 2 per share)

181.173

180.940

181.173

18

Reserves & Surplus excluding Revaluation Reserve as per balance

sheet of previous accounting year.

--

--

--

19

a) Basic Earnings per share-not annualized before & after extraordinay items - Rs.

4.00

3.99

7.99

 

b) Diluted earnings per share after Employees Stock Options before & after extraordinay items - Rs.

3.99

3.98

7.97

 

 

 

 

 

PART - II   

A

PARTICULARS OF SHAREHOLDING

 

 

 

1

Public shareholding

 

 

 

 

a.

Number of shares

4,50,76,051

4,52,17,748

4,50,76,051

 

b.

Percentage of shareholding

49.76%

49.98%

49.76%

2

Promoters and promoter group shareholding

 

 

 

 

a.

Pledged/Encumbered

 

 

 

 

Number of shares

Nil

Nil

Nil

 

 

Percentage of shares (as a % of the total shareholding of promoter and promoter group)

                           Nil

Nil

Nil

 

 

Percentage of shares (as a % of the total share capital of the Company)

Nil

Nil

Nil

 

b.

Non-encumbered

 

 

 

 

Number of shares

4,55,10,550

4,52,52,440

4,55,10,550

 

 

Percentage of shares (as a % of the total shareholding of promoter and promoter group)

100.00%

100.00%

100.00%

 

 

Percentage of shares (as a % of the total share capital of the Company)

50.24%

50.02%

50.24%

 

 

Particulars

Quarter

ended

30.09.2013

B   INVESTOR COMPLAINTS (Nos.)

 

Pending at the beginning of the quarter

Nil

Received during the quarter

7

Disposed of during the quarter

7

Remaining unresolved at the end of the quarter

Nil

 

Notes :

1 The above results have been subjected to Limited Review by the Statutory Auditors, reviewed by the Audit Committee and taken on record by the Board of Directors of the Company in its meeting held on 19th October, 2013.

 

2 Segment Reporting: Primary Segment

The Company has only one segment i.e. 'Pharmaceuticals'

Secondary Segment (By Geographical Segment)

 

(Rs. In Millions)

Net Sales and Operating IncomeNet Sales and Operating Income

Three months

 ended

30.09.2013

Three months

 ended

30.06.2013

Half year

ended

30.09.2013

 

(Unaudited)

(Unaudited)

(Unaudited)

Within India

1809.025

1810.376

3619.401

Outside India

886.687

845.412

1732.099

Total

2695.712

2655.788

5351.500

Total

 

 

 

 

In view of the interwoven / intermix nature of the business and manufacturing facility, other segmental information is not ascertainable.

 

3 Other Income / Other expenses includes exchange gain / loss as under:

 

Exchange Difference

Three months

 ended

30.09.2013

Three months

 ended

30.06.2013

Half year

ended

30.09.2013

 

(Unaudited)

(Unaudited)

(Unaudited)

Exchange gain included in Other Income

40.801

52.518

93.019

Exchange loss included in Other Expenses

--

--

--

 

4 Unaudited Statement of Assets and Liabilities as on 30.09.2013

 

(Rs. In Millions)

Particular

30.09.2013

 

EQUITY AND LIABILITIES

 

Shareholders’ funds

 

(a) Share capital

181.173

(b) Reserves and surplus

8678.686

Sub-total - Shareholders' funds

8859.859

 

 

Share Application Money pending allotment

--

 

 

Non-current liabilities

 

(a) Long-term borrowings

254.852

(b) Deferred Tax Liabilities (Net)

401.743

(c) Long term provisions

135.270

Sub-total - Non-current liabilities

791.865

 

 

Current liabilities

 

(a) Short term borrowings

141.807

(b) Trade payables

1577.723

(c) Other current liabilities

297.920

(d) Short -term provisions

8.165

Sub-total - Current liabilities

2025.615

TOTAL - EQUITY AND LIABILITIES

11677.339

 

 

ASSETS

 

Non-current assets

 

(a) Fixed assets

 

(i) Tangible assets

4974.716

(i) Intangible assets

100.676

(i) Capital wok-in-progress

603.653

 

5679.045

 

 

(b) Non-current investments

 

(c) Long-term loans and advances

 

Sub-total - Non-current assets Current assets

 

Current assets

 

(a)Current Investments

60.000

(b) Inventories

1453.106

(c) Trade receivables

2299.858

(d) Cash and cash equivalents

187.417

(f) Short-term loans and advances

787.257

(g) Other current assets

37.270

Sub-total - Current assets

4824.908

TOTAL - ASSETS

11677.339

 

 

FIXED ASSETS

 

v                             Tangible Assets

Land

Plant and Equipments

Furniture and Fixtures

Vehicles

Office Equipments

 

v                             Intangible Assets

Brands / trademarks

 

 

PRESS RELEASE

 

UNICHEM LABORATORIES RECEIVES ANDA APPROVAL FROM USFDA FOR AMLODIPINE BESYLATE TABLETS

 

Mumbai, Thursday, October 24, 2013

Unichem laboratories Limited are pleased to announce that it has received ANDA approval from the United States Food and Drug Administration (U.S. FDA) for Amlodipine Besylate Tablets.

 

Amlodipine Besylate Tablets USP 2.5mg, 5mg and 10mg are therapeutically equivalent to NORVASC® Tablets 2.5mg, 5mg and 10mg from Pfizer Inc.

 

Amlodipine Besylate Tablet USP is a calcium channel blocker indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. The product will be commercialized from Unichem’s Goa plant. Active pharmaceutical ingredient i.e., Amlodipine Besylate used for this ANDA is also made in house at Roha plant.

 

Currently, there are 6-7 companies are dominating the US market. The current market size is around US$ 45~50 Million.

 

About Unichem Laboratories Limited

 

Unichem Laboratories Limited is an International, integrated, speciality pharmaceutical Company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world. In India, the Company is a leaded in niche areas of cardiology, neurology and other orthopadics and anti-infectives. The Company has strong skills in product development, process chemistry and manufacturing of complex API as well as dosage forms.

 

INDEX OF CHARGES

 

S.NO.

CHARGE ID

DATE OF CHARGE CREATION/MODIFICATION

CHARGE AMOUNT SECURED

CHARGE HOLDER

ADDRESS

SERVICE REQUEST NUMBER (SRN)

1

90238025

29/01/1993 *

375,000,000.00

BANK OF INDIA

CUMBALLA HILL BRANCH, N.S. PATKAR MARG, MUMBAI - 400036, MAHARASHTRA, INDIA

-

2

90234683

14/08/2001 *

150,000,000.00

ICICI LIMITED

ICICI TOWER, BANDRA KURLA COMPLEX, MUMBAI - 400051, MAHARASHTRA, INDIA

-

3

90237983

30/04/2001 *

100,000,000.00

BIRLA SUNLIFE ASSET MANAGEMENT CO. LTD.

AHURA CENTRE TOWER A, ANDHERI, MUMBAI - 400093, MAHARASHTRA, INDIA

-

4

90237977

14/01/2000

253,690,000.00

BANK OF INDIA

CUMBALLA HILL BRANCH, N.S. PATKAR MARG, MUMBAI - 400036, MAHARASHTRA, INDIA

-

5

90234504

23/02/1999

253,690,000.00

BANK OF INDIA

CUMBALLA HILL BRANCH, N.S. PATKAR MARG, MUMBAI - 400036, MAHARASHTRA, INDIA

-

6

90237911

18/06/2002 *

104,294,000.00

BANK OF INDIA

NIRMALCUMBALLA HILL BRANCH, NARIMAN POINT, MUMBAI - 400036, MAHARASHTRA, INDIA

-

7

90234023

13/07/1994

6,000,000.00

THE SAKURA BANK LTD.

MITTAL COURT, NARIMAN POINT, MUMBAI - 400021, MAHARASHTRA , INDIA

-

8

90233819

17/03/1992

15,000,000.00

I.D.B.I.

IDBI TOWER, CUFFE PARADE, MUMBAI, MAHARASHTRA - 400005, INDIA

-

9

90233781

01/10/1991

18,200,000.00

THE MITSUI TALYO KOBE BANK LTD.

NARIMAN POINT, MUMBAI - 400021, MAHARASHTRA, INDIA

-

10

90233735

12/04/1991

14,200,000.00

THE MITSUI TAIYO KOBE BANK LTD.

NARIMAN POINT, MUMBAI - 400021, MAHARASHTRA, INDIA

-

11

90233636

13/01/1990

13,100,000.00

THE MITSUI BANK LTD.

NARIMAN POINT, MUMBAI - 400021, MAHARASHTRA, INDIA

-

12

90233530

15/05/1989 *

5,000,000.00

BANK OF BARODA

CUMBALLA HILL BRANCH, N.S. PATKAR MARG, MUMBAI - 400036, MAHARASHTRA, INDIA

-

13

90233528

06/12/1989 *

5,000,000.00

BANK OF BARODA

CUMBALLA HILL BRANCH, N.S. PATKAR MARG, MUMBAI - 400036, MAHARASHTRA, INDIA

-

14

90233499

27/03/1988

5,000,000.00

BANK OF INDIA

CUMBALLA HILL BRANCH, N.S. PATKAR MARG, MUMBAI - 400036, MAHARASHTRA, INDIA

-

15

90233405

29/01/1987

496,340.00

HINDUSTAN PETROLEUM CORP. LTD.

PETROLEUM HOUSE, TATA ROAD, MUMBAI - 
400020, MAHARASHTRA, INDIA

-

16

90233289

25/01/1988 *

10,000,000.00

THE INDUSTRIAL CREDIT AND INVEST. CORP. OF INIDA L 
IMITED

163; BACKBAY RECLAMATION, MUMBAI - 400020, MAHARASHTRA, INDIA

-

17

90237816

29/12/1981

96,900.00

GOVERNOR OF U.P.

U. P. FINANCIAL CORPORATION, U. P. FINANCIAL COR, 
MAHARASHTRA, INDIA

-

18

90233099

21/11/1980

2,500,000.00

LIFE INSURANCE CORP. OF INDIA

YOGAKSHEMA, JEEVAN BIMA MARG, BOMBAY, MAHARASHTRA 
- 400021, INDIA

-

19

90232979

04/01/1975

1,500,000.00

THE PRADESHIYA INDUSTRIAL AND INVEST; CORP. OF U.P . LTD.

VIVEKANAND MARG, LUCKNOW - 226001, UTTAR PRADESH, 
INDIA

-

20

90232970

14/03/1974

15,100,000.00

GOVERNOR OF U.P.

U. P. FINANCIAL CORPORATION, U. P. FINANCIAL COR, 
MAHARASHTRA, INDIA

-

21

90237795

27/12/1973

360,000.00

UTTAR PRADESH FINACIAL CORP.

KANPUR, KANPUR, UTTAR PRADESH, INDIA

-

22

90237788

03/11/1970

315,000.00

UNICHEM LABORATORIES LTD.

S.V. ROAD, FORT, MUMBAI - 400060, MAHARASHTRA, INDIA

-

23

90237787

27/10/1969

750,000.00

UTTAR PRADESH FINANCIAL CORP.

KANPUR, KANPUR, UTTAR PRADESH, INDIA

-

24

90232926

18/11/1966

100,000.00

THE BANK OF INDIA

JANPATH, NEW DELHI, DELHI, INDIA

-

25

90232916

27/05/1963

1,500,000.00

BANK OF INDIA

M.G. ROAD, FORT, BOMBAY, MAHARASHTRA, INDIA

-

 

* Date of charge modification

 

 

 


 

CMT REPORT (Corruption, Money Laundering & Terrorism]

 

The Public Notice information has been collected from various sources including but not limited to: The Courts, India Prisons Service, Interpol, etc.

 

1]         INFORMATION ON DESIGNATED PARTY

No exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.

 

2]         Court Declaration :

No records exist to suggest that subject is or was the subject of any formal or informal allegations, prosecutions or other official proceeding for making any prohibited payments or other improper payments to government officials for engaging in prohibited transactions or with designated parties.

 

3]         Asset Declaration :

No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.

 

4]         Record on Financial Crime :

            Charges or conviction registered against subject:                                                              None

 

5]         Records on Violation of Anti-Corruption Laws :

            Charges or investigation registered against subject:                                                          None

 

6]         Records on Int’l Anti-Money Laundering Laws/Standards :

            Charges or investigation registered against subject:                                                          None

 

7]         Criminal Records

No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.

 

8]         Affiliation with Government :

No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.

 

9]         Compensation Package :

Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.

 

10]        Press Report :

            No press reports / filings exists on the subject.

 


 

CORPORATE GOVERNANCE

 

MIRA INFORM as part of its Due Diligence do provide comments on Corporate Governance to identify management and governance. These factors often have been predictive and in some cases have created vulnerabilities to credit deterioration.

 

Our Governance Assessment focuses principally on the interactions between a company’s management, its Board of Directors, Shareholders and other financial stakeholders.

 

 

CONTRAVENTION

 

Subject is not known to have contravened any existing local laws, regulations or policies that prohibit, restrict or otherwise affect the terms and conditions that could be included in the agreement with the subject.

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.62.33

UK Pound

1

Rs.102.18

Euro

1

Rs.84.68

 

 

INFORMATION DETAILS

 

Report Prepared by :

DPH

 


 

SCORE & RATING EXPLANATIONS

 

SCORE FACTORS

 

RANGE

POINTS

HISTORY

1~10

8

PAID-UP CAPITAL

1~10

8

OPERATING SCALE

1~10

7

FINANCIAL CONDITION

 

 

--BUSINESS SCALE

1~10

7

--PROFITABILIRY

1~10

7

--LIQUIDITY

1~10

7

--LEVERAGE

1~10

7

--RESERVES

1~10

7

--CREDIT LINES

1~10

6

--MARGINS

-5~5

--

DEMERIT POINTS

 

 

--BANK CHARGES

YES/NO

YES

--LITIGATION

YES/NO

YES

--OTHER ADVERSE INFORMATION

YES/NO

NO

MERIT POINTS

 

 

--SOLE DISTRIBUTORSHIP

YES/NO

NO

--EXPORT ACTIVITIES

YES/NO

NO

--AFFILIATION

YES/NO

YES

--LISTED

YES/NO

NO

--OTHER MERIT FACTORS

YES/NO

YES

DEFAULTER

 

 

--RBI

YES/NO

NO

--EPF

YES/NO

NO

TOTAL

 

64

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 


 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

                                       New Business

 

--

 

 

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.